What the FTC's Amare suit means for wellness brands that sell through affiliates
The FTC sued Amare Global on June 2 over supplement claims its brand partners made on social media. If you sell through affiliates, their posts are your liability.
On June 2, the FTC sued supplement seller Amare Global Holdings and three of its principals in California federal court. The agency alleges the company and its sellers marketed dietary supplements as treatments for depression, anxiety, and ADHD in both children and adults, including claims that one product could reduce the risk of suicide in children. The FTC also says Amare misled the people it recruited to sell those products, telling them they could earn $500 a month or replace their income when the company’s own disclosures showed a typical distributor making about $25 a month before expenses. The allegations are unproven, but the structure of the case is what wellness operators should study.
The detail that matters most is who made the claims. The FTC’s complaint points to posts on Instagram, TikTok, YouTube, and Facebook, many of them made by Amare’s brand partners rather than the company’s own marketing department. This is the trap. Plenty of wellness brands have convinced themselves that an ambassador program or an affiliate network puts legal distance between the company and the things being said about the product. It does the opposite. The FTC has treated a brand’s affiliates as its agents for years, and the disclosures and substantiation rules apply to what those affiliates say, not just to what the brand says in its own voice. If your sellers are making claims you could not make yourself, you are not insulated. You are on the hook for all of it.
The second lesson is about disease claims. There is a hard line between describing a product as supporting general wellness and describing it as treating a diagnosed condition. The moment a supplement is positioned as treating depression, anxiety, or ADHD, it is being marketed as a drug, and it needs the kind of competent and reliable scientific evidence the FTC requires for any health claim, plus exposure under FDA’s drug rules. Aiming those claims at children, or attaching them to suicide risk, moves the conduct from a routine substantiation dispute into the category the agency prioritizes for aggressive enforcement. No amount of “these statements have not been evaluated by the FDA” boilerplate cures a claim that the product treats a disease.
The third lesson is that earnings claims carry their own liability. If you run any kind of referral, affiliate, or multilevel structure, the income you suggest a recruit can earn has to match what your actual participants earn. A typical-results figure you cannot back with your own payout data is its own deceptive practice, independent of anything said about the product.
The concrete action this quarter is to pull the last ninety days of posts from every affiliate, ambassador, and brand partner who promotes your product, read them against what you could lawfully say yourself, and put a written, enforced claims policy in front of anyone authorized to speak about what you sell.